ClinicalTrials.gg
CompletedNCT01531673Updated Apr 13, 2018Results posted

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

A Phase 2 interventional study of VX-661 and Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 36 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-04-13.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
10th of 43
194 · median 100
Started
2012
the only one that year
Phase 2
8 of 43
none open now
Registered
1st of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 10th largest by enrollment, is the only one that started in 2012, is one of 8 in phase 2, and was the 1st registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) effects of VX-661 alone and when coadministered with ivacaftor in participants with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del-CFTR mutation.

Read the detailed description

This is a Phase 2, randomized, multicenter, double-blinded, placebo-controlled, study of VX-661 monotherapy, and VX-661/ivacaftor co-therapy in participants with CF who are homozygous or heterozygous for the F508del CFTR mutation.

This study is separated into seven groups: Group 1-7, respectively. Approximately 180 participants were randomized in a ratio of 4:1; active drug to matching placebo in each group.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female with confirmed diagnosis of CF
  • Must have the F508del-CFTR gene mutation in both alleles (Groups 1, 2, 3, 4, 5, 6). Group 7 participants must have the F508del-CFTR mutation on 1 allele, and gating mutation G551D on the second allele and have been on their physician prescribed 150 mg KalydecoTM q12h (commercially available ivacaftor) for at least 28 days at the Screening Visit.
  • (FEV1) 40% to 90% (inclusive) of predicted normal for age, gender, and height (Knudson standards) at screening
  • Weight >40 kg and >18.5
  • Participants of and who are sexually active must meet the requirements.

Exclusion criteria

Exclusion Criteria:

  • History of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant.
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before Study Day 1.
  • History of solid organ or hematological transplantation
  • Participation in a clinical study involving administration of either an or a marketed drug within 30 days or 5 terminal half-lives (whichever is longer) before screening
  • History of alcohol, medication, or illicit drug abuse within 1 year prior to screening
  • Pregnant, breast-feeding, or not willing to follow requirements
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
194 participants (actual)

Study arms

  • Placebo comparator
    Group 1-6d Combined: Placebo

    All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.

    Drug: Placebo matched to VX-661 · Drug: Placebo matched to ivacaftor

  • Experimental
    Group 1: VX-661 10 mg qd

    All participants in group 1 who received VX-661 10 milligram (mg) tablet orally once daily (qd) for up to 28 days.

    Drug: VX-661

  • Experimental
    Group 2a: VX-661 30 mg qd

    All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet every 12 hours (q12h) for up to 28 days.

    Drug: VX-661 · Drug: Placebo matched to ivacaftor

  • Experimental
    Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h

    All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.

    Drug: VX-661 · Drug: Ivacaftor

  • Experimental
    Group 3a: VX-661 100 mg qd

    All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.

    Drug: VX-661 · Drug: Placebo matched to ivacaftor

  • Experimental
    Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h

    All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.

    Drug: VX-661 · Drug: Ivacaftor

  • Experimental
    Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h

    All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.

    Drug: VX-661 · Drug: Ivacaftor

  • Experimental
    Group 5a: VX-661 150 mg qd

    All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.

    Drug: VX-661

  • Experimental
    Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h

    All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.

    Drug: VX-661 · Drug: Ivacaftor

  • Experimental
    Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h

    All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.

    Drug: VX-661 · Drug: Ivacaftor

  • Experimental
    Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h

    All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.

    Drug: VX-661 · Drug: Ivacaftor

  • Placebo comparator
    Group 7: Placebo

    All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.

    Drug: Ivacaftor · Drug: Placebo matched to VX-661

  • Experimental
    Group 7: VX-661 100 mg qd

    All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.

    Drug: VX-661 · Drug: Ivacaftor

Interventions

  • DrugVX-661
  • DrugPlacebo matched to VX-661
  • DrugPlacebo matched to ivacaftor
06

What researchers measure

Primary outcomes

  1. Safety as Determined by Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the Informed Consent Form is signed. AE includes serious as well as non-serious AEs. Serious Adverse Event (SAE) is any AE that results in any of the following: death; life-threatening condition; inpatient hospitalization or prolongation of hospitalization; persistent or significant disability or incapacity; congenital anomaly or birth defect; or other important medical event. Treatment-emergent adverse events are defined as adverse events that were reported or worsened on or after start of study drug through the Follow-up Visit (28 days after last dose of study drug) or premature discontinuation.

    Time frame: Start of study drug through the Follow-up Visit (Up to Day 56)

  2. Change in Sweat Chloride From Baseline Through Study Day 28 for Group 1-5b

    Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.

    Time frame: Baseline through Day 28

  3. Change in Sweat Chloride From Baseline Through Study Day 28 for Group 6

    Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.

    Time frame: Baseline through Day 28

  4. Change in Sweat Chloride From Baseline Through Study Day 28 for Group 7

    Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.

    Time frame: Baseline through Day 28

Secondary outcomes

  1. Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 1-5b

    Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.

    Time frame: Baseline, Day 7, Day 14, Day 21, Day 28

  2. Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 6

    Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.

    Time frame: Baseline, Day 7, Day 14, Day 21, Day 28

  3. Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 7

    Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.

    Time frame: Baseline, Day 7, Day 14, Day 21, Day 28

  4. Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Day 7, Day 14, Day 21, Day 28

  5. Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.

    Time frame: Baseline, Day 7, Day 14, Day 21, Day 28

  6. Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Day 7, Day 14, Day 21, Day 28

  7. Change in FEV1 (Liter [L]) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Day 7, Day 14, Day 21, Day 28

  8. Change in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.

    Time frame: Baseline, Day 7, Day 14, Day 21, Day 28

  9. Change in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: Baseline, Day 7, Day 14, Day 21, Day 28

  10. Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: Baseline, Day 14, Day 28

  11. Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.

    Time frame: Baseline, Day 14, Day 28

  12. Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: Baseline, Day 14, Day 28

  13. Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661 After Administration of VX-661 Monotherapy

    Participants who received VX-661 monotherapy (Group 1, 2a, 3a and 5a) were analyzed for this outcome measure. PK analysis (AUC0-24h) was not planned for placebo reporting arms.

    Time frame: Day 28

  14. AUC0-24h of VX-661 and AUC0-12h of Ivacaftor After Administration of VX-661 in Combination With Ivacaftor

    Participants who received VX-661 in combination with Ivacaftor (Group 2b, 3b, 4, 5b, 6a, 6d and 7) were analyzed for this outcome measure. PK analysis was not planned for placebo reporting arms.

    Time frame: Day 28

07

Results

Posted Apr 13, 2018
Limitations and caveats
Pharmacokinetic (PK) final data are not yet available. Once the data are available for PK endpoints, the posting will be updated to include the same.

Participant flow

Participant flow — Overall Study
MilestoneGroup 1-6d Combined: PlaceboGroup 1: VX-661 10 mg qdGroup 2a: VX-661 30 mg qdGroup 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12hGroup 3a: VX-661 100 mg qdGroup 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12hGroup 4: VX-661 100 mg qd/Ivacaftor 150 mg q12hGroup 5a: VX-661 150 mg qdGroup 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12hGroup 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12hGroup 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12hGroup 7: PlaceboGroup 7: VX-661 100 mg qd
Started338818819179171916414
Completed337817718179171816414
Not completed0101110001000
Withdrew: Non-compliance0000010000000
Withdrew: Adverse event0100000000000
Withdrew: Lost to follow-up0000100000000
Withdrew: Other0001000001000

Outcome measures

PrimarySafety as Determined by Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the Informed Consent Form is signed. AE includes serious as well as non-serious AEs. Serious Adverse Event (SAE) is any AE that results in any of the following: death; life-threatening condition; inpatient hospitalization or prolongation of hospitalization; persistent or significant disability or incapacity; congenital anomaly or birth defect; or other important medical event. Treatment-emergent adverse events are defined as adverse events that were reported or worsened on or after start of study drug through the Follow-up Visit (28 days after last dose of study drug) or premature discontinuation.

Time frame:
Start of study drug through the Follow-up Visit (Up to Day 56)
Reported as:
Number · participants
Safety as Determined by Adverse Events (AEs)
participantsGroup 1-6d Combined: PlaceboGroup 1: VX-661 10 mg qdGroup 2a: VX-661 30 mg qdGroup 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12hGroup 3a: VX-661 100 mg qdGroup 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12hGroup 4: VX-661 100 mg qd/Ivacaftor 150 mg q12hGroup 5a: VX-661 150 mg qdGroup 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12hGroup 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12hGroup 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12hGroup 7: PlaceboGroup 7: VX-661 100 mg qd
Participants with AEs308715718108171616212
Participants with SAEs5111022001201
PrimaryChange in Sweat Chloride From Baseline Through Study Day 28 for Group 1-5b

Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.

Time frame:
Baseline through Day 28
Reported as:
Least squares mean · millimole per liter (mmol/L)
Change in Sweat Chloride From Baseline Through Study Day 28 for Group 1-5b
millimole per liter (mmol/L)Group 1: VX-661 10 mg qdGroup 2a: VX-661 30 mg qdGroup 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12hGroup 3a: VX-661 100 mg qdGroup 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12hGroup 4: VX-661 100 mg qd/Ivacaftor 150 mg q12hGroup 5a: VX-661 150 mg qdGroup 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12hGroup 1-5b Combined Placebo
Change in Sweat Chloride From Baseline Through Study Day 28 for Group 1-5b3.92 (-0.5 to 8.34)-4.76 (-9.75 to 0.22)-5.06 (-8.02 to -2.09)-20.43 (-24.75 to -16.12)-6 (-8.98 to 3.02)-6.04 (-9.12 to -2.96)-10.46 (-14.53 to -6.39)-2.63 (-5.67 to 0.41)-0.86 (-3.36 to 1.65)
Statistical analysis
  • Group 1: VX-661 10 mg qd vs Group 1-5b Combined Placebo · Mixed-effect repeated measure (MMRM) · p = 0.0647 · Least squares (ls) mean difference: 4.77 · 95% CI -0.3 to 9.84
  • Group 2a: VX-661 30 mg qd vs Group 1-5b Combined Placebo · MMRM · p = 0.1686 · Ls mean difference: -3.91 · 95% CI -9.5 to 1.68
  • Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h vs Group 1-5b Combined Placebo · MMRM · p = 0.0348 · Ls mean difference: -4.2 · 95% CI -8.1 to -0.31
  • Group 3a: VX-661 100 mg qd vs Group 1-5b Combined Placebo · MMRM · p = <0.0001 · Ls mean difference: -19.58 · 95% CI -24.57 to -14.59
  • Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h vs Group 1-5b Combined Placebo · MMRM · p = 0.0101 · Ls mean difference: -5.14 · 95% CI -9.03 to -1.25
  • Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h vs Group 1-5b Combined Placebo · MMRM · p = 0.011 · Ls mean difference: -5.19 · 95% CI -9.16 to -1.21
  • Group 5a: VX-661 150 mg qd vs Group 1-5b Combined Placebo · MMRM · p = 0.0001 · Ls mean difference: -9.6 · 95% CI -14.38 to -4.82
  • Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h vs Group 1-5b Combined Placebo · MMRM · p = 0.3745 · Ls mean difference: -1.77 · 95% CI -5.71 to 2.17
PrimaryChange in Sweat Chloride From Baseline Through Study Day 28 for Group 6

Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.

Time frame:
Baseline through Day 28
Reported as:
Least squares mean · mmol/L
Change in Sweat Chloride From Baseline Through Study Day 28 for Group 6
mmol/LGroup 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12hGroup 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12hGroup 4 and 6 Combined: Placebo
Change in Sweat Chloride From Baseline Through Study Day 28 for Group 6-6.07 (-10.84 to -1.31)-7.89 (-12.3 to -3.48)-1.19 (-5.5 to 3.12)
Statistical analysis
  • Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h vs Group 4 and 6 Combined: Placebo · MMRM · p = 0.0357 · Ls mean difference: -6.7 · 95% CI -12.94 to -0.46
PrimaryChange in Sweat Chloride From Baseline Through Study Day 28 for Group 7

Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.

Time frame:
Baseline through Day 28
Reported as:
Least squares mean · mmol/L
Change in Sweat Chloride From Baseline Through Study Day 28 for Group 7
mmol/LGroup 7: PlaceboGroup 7: VX-661 100 mg qd
Change in Sweat Chloride From Baseline Through Study Day 28 for Group 710.18 (-2.48 to 22.84)-7.02 (-14.15 to 0.11)
Statistical analysis
  • Group 7: Placebo vs Group 7: VX-661 100 mg qd · MMRM · p = 0.0238 · Ls mean difference: -17.2 · 95% CI -31.75 to -2.65
SecondaryChange in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 1-5b

Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.

Time frame:
Baseline, Day 7, Day 14, Day 21, Day 28
Reported as:
Least squares mean · mmol/L
Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 1-5b
mmol/LGroup 1: VX-661 10 mg qdGroup 2a: VX-661 30 mg qdGroup 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12hGroup 3a: VX-661 100 mg qdGroup 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12hGroup 4: VX-661 100 mg qd/Ivacaftor 150 mg q12hGroup 5a: VX-661 150 mg qdGroup 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12hGroup 1-5b Combined Placebo
Day 71.73 (-3.82 to 7.29)-3.13 (-9.5 to 3.25)-5.37 (-9.24 to -1.49)-19.48 (-25 to -13.97)-5.02 (-8.85 to -1.19)-6.85 (-10.72 to -2.99)-13.89 (-19.09 to -8.69)-0.59 (-4.38 to 3.2)0.22 (-3.01 to 3.45)
Day 140.91 (-4.64 to 6.46)-7.88 (-14.25 to -1.5)-6.55 (-10.34 to -2.76)-28.23 (-33.75 to 22.72)-6.77 (-10.81 to -2.74)-7.37 (-11.44 to -3.3)-10.28 (-15.48 to -5.08)-2.4 (-6.38 to 1.58)-1.32 (-4.5 to 1.87)
Day 214.84 (-0.99 to 10.66)-4.61 (-10.98 to 1.76)-3.7 (-7.48 to 0.09)-18.78 (-24.3 to -13.27)-5.83 (-9.77 to -1.89)-4.26 (-8.44 to -0.08)-12.17 (-17.37 to -6.97)-3.9 (-7.88 to 0.08)-1.05 (-4.29 to 2.18)
Day 288.19 (2.37 to 14.02)-3.44 (-9.82 to 2.93)-4.62 (-8.41 to -0.83)-15.23 (-20.75 to -9.72)-6.37 (-10.22 to -2.52)-5.68 (-9.76 to -1.61)-5.5 (-10.7 to 0.3)-3.62 (-7.6 to 0.36)-1.27 (-4.55 to 2.01)
SecondaryChange in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 6

Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.

Time frame:
Baseline, Day 7, Day 14, Day 21, Day 28
Reported as:
Least squares mean · mmol/L
Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 6
mmol/LGroup 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12hGroup 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12hGroup 4 and 6 Combined: Placebo
Day 7-6.61 (-12.06 to -1.16)-11.04 (-16.37 to -5.7)-0.36 (-5.54 to 4.83)
Day 14-7.9 (-13.25 to -2.55)-7.11 (-12.34 to -1.88)-2.1 (-7.19 to 2.98)
Day 21-6.34 (-12 to 0.68)-6.98 (-12.2 to -1.76)-2.47 (-7.67 to 2.72)
Day 28-3.44 (-8.85 to 1.97)-6.43 (-11.55 to -1.31)0.19 (-5.01 to 5.39)
SecondaryChange in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 7

Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.

Time frame:
Baseline, Day 7, Day 14, Day 21, Day 28
Reported as:
Least squares mean · mmol/L
Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 7
mmol/LGroup 7: PlaceboGroup 7: VX-661 100 mg qd
Day 74.87 (-8.32 to 18.06)-7.28 (-14.76 to 0.2)
Day 1410.75 (-2.44 to 23.94)-8.95 (-16.54 to -1.35)
Day 219.37 (-3.82 to 22.56)-4.14 (-11.86 to 3.58)
Day 2815.73 (1.85 to 29.61)-7.72 (-15.31 to -0.13)
SecondaryChange in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Day 7, Day 14, Day 21, Day 28
Reported as:
Least squares mean · percent predicted of FEV1
Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b
percent predicted of FEV1Group 1: VX-661 10 mg qdGroup 2a: VX-661 30 mg qdGroup 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12hGroup 3a: VX-661 100 mg qdGroup 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12hGroup 4: VX-661 100 mg qd/Ivacaftor 150 mg q12hGroup 5a: VX-661 150 mg qdGroup 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12hGroup 1-5b Combined Placebo
Post-Baseline Through Day 283.49 (0.21 to 6.77)1.63 (-1.62 to 4.87)1.3 (-0.87 to 3.47)1.6 (-1.64 to 4.85)2.9 (0.76 to 5.03)3.75 (1.47 to 6.02)2.54 (-0.53 to 5.61)3.61 (1.36 to 5.86)-0.14 (-2.02 to 1.74)
Day 72.72 (-1.17 to 6.62)0.8 (-3.09 to 4.69)0.47 (-2.13 to 3.06)3 (-0.89 to 6.89)2.9 (0.37 to 5.42)2.66 (-0.01 to 5.33)0.5 (-3.17 to 4.18)2.51 (-0.16 to 5.18)-0.41 (-2.66 to 1.84)
Day 145.25 (1.35 to 9.15)3.72 (-0.17 to 7.61)0.91 (-1.69 to 3.5)1.61 (-2.28 to 5.5)1.79 (-0.78 to 4.36)4.52 (1.73 to 7.3)2.79 (-1 to 6.59)3.72 (1 to 6.44)0.03 (-2.21 to 2.28)
Day 212.71 (-1.34 to 6.76)1.8 (-2.09 to 5.69)1.84 (-0.75 to 4.44)0.25 (-3.64 to 4.15)3.88 (1.27 to 6.5)3.37 (0.58 to 6.15)4.52 (0.85 to 8.19)4.08 (1.36 to 6.8)0.18 (-2.07 to 2.43)
Day 283.26 (-0.79 to 7.32)0.19 (-3.7 to 4.08)1.99 (-0.65 to 4.63)1.55 (-2.34 to 5.45)3.02 (0.4 to 5.63)4.44 (1.66 to 7.23)2.34 (-1.33 to 6.01)4.13 (1.41 to 6.86)-0.36 (-2.63 to 1.92)
SecondaryChange in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.

Time frame:
Baseline, Day 7, Day 14, Day 21, Day 28
Reported as:
Least squares mean · percent predicted of FEV1
Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6
percent predicted of FEV1Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12hGroup 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12hGroup 4 and 6 Combined: Placebo
Post-Baseline Through Day 280.94 (-1.42 to 3.3)2.31 (-0.19 to 4.8)1.47 (-1.2 to 4.13)
Day 71.37 (-1.33 to 4.08)1.95 (-0.93 to 4.82)1.09 (-1.97 to 4.15)
Day 141.2 (-1.55 to 3.95)2.52 (-0.36 to 5.4)1.37 (-1.69 to 4.44)
Day 210.36 (-2.38 to 3.11)3.21 (0.33 to 6.08)1.73 (-1.39 to 4.85)
Day 280.81 (-1.97 to 3.6)1.56 (-1.32 to 4.44)1.67 (-1.45 to 4.8)
SecondaryChange in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Day 7, Day 14, Day 21, Day 28
Reported as:
Least squares mean · percent predicted of FEV1
Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7
percent predicted of FEV1Group 7: PlaceboGroup 7: VX-661 100 mg qd
Post-Baseline Through Day 281.4 (-5.04 to 7.83)4.6 (1.17 to 8.03)
Day 73 (-3.55 to 9.55)4.14 (0.65 to 7.63)
Day 140.98 (-5.56 to 7.53)5.22 (1.73 to 8.71)
Day 212.72 (-3.83 to 9.27)3.88 (0.39 to 7.38)
Day 28-1.12 (-7.66 to 5.43)5.16 (1.67 to 8.65)
SecondaryChange in FEV1 (Liter [L]) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Day 7, Day 14, Day 21, Day 28
Reported as:
Least squares mean · Liters
Change in FEV1 (Liter [L]) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b
LitersGroup 1: VX-661 10 mg qdGroup 2a: VX-661 30 mg qdGroup 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12hGroup 3a: VX-661 100 mg qdGroup 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12hGroup 4: VX-661 100 mg qd/Ivacaftor 150 mg q12hGroup 5a: VX-661 150 mg qdGroup 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12hGroup 1-5b Combined Placebo
PB Through Day 280.14 (0.02 to 0.26)0.07 (-0.05 to 0.19)0.05 (-0.03 to 0.13)0.04 (-0.08 to 0.16)0.1 (0.02 to 0.18)0.14 (0.06 to 0.23)0.1 (-0.01 to 0.21)0.12 (0.04 to 0.21)0.01 (-0.06 to 0.08)
Day 70.11 (-0.04 to 0.25)0.02 (-0.13 to 0.16)0.02 (-0.08 to 0.12)0.09 (-0.06 to 0.24)0.1 (0 to 0.19)0.11 (0.01 to 0.21)0.02 (-0.12 to 0.16)0.08 (-0.02 to 0.18)-0.01 (-0.09 to 0.08)
Day 140.2 (0.05 to 0.34)0.14 (-0.01 to 0.28)0.03 (-0.07 to 0.12)0.04 (-0.11 to 0.19)0.05 (-0.04 to 0.15)0.17 (0.06 to 0.27)0.11 (-0.03 to 0.25)0.12 (0.02 to 0.23)0.02 (-0.07 to 0.1)
Day 210.12 (-0.03 to 0.27)0.08 (-0.06 to 0.23)0.07 (-0.03 to 0.17)0 (-0.15 to 0.15)0.14 (0.04 to 0.23)0.13 (0.02 to 0.23)0.18 (0.04 to 0.31)0.14 (0.04 to 0.24)0.02 (-0.06 to 0.1)
Day 280.13 (-0.02 to 0.28)0.03 (-0.11 to 0.18)0.08 (-0.02 to 0.18)0.04 (-0.11 to 0.18)0.1 (0.01 to 0.2)0.16 (0.06 to 0.27)0.09 (-0.05 to 0.23)0.15 (0.05 to 0.26)0.01 (-0.08 to 0.09)
SecondaryChange in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.

Time frame:
Baseline, Day 7, Day 14, Day 21, Day 28
Reported as:
Least squares mean · Liters
Change in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6
LitersGroup 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12hGroup 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12hGroup 4 and 6 Combined: Placebo
Post-Baseline Through Day 280.02 (-0.07 to 0.11)0.09 (-0.01 to 0.18)0.07 (-0.04 to 0.17)
Day 70.04 (-0.07 to 0.14)0.06 (-0.05 to 0.17)0.05 (-0.06 to 0.17)
Day 140.03 (-0.07 to 0.14)0.1 (-0.01 to 0.21)0.06 (-0.05 to 0.18)
Day 21-0.01 (-0.11 to 0.1)0.13 (0.02 to 0.24)0.08 (-0.04 to 0.2)
Day 280.02 (-0.08 to 0.13)0.06 (-0.05 to 0.17)0.08 (-0.04 to 0.2)
SecondaryChange in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
Baseline, Day 7, Day 14, Day 21, Day 28
Reported as:
Least squares mean · Liters
Change in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7
LitersGroup 7: PlaceboGroup 7: VX-661 100 mg qd
Post-Baseline Through Day 280.09 (-0.16 to 0.34)0.16 (0.03 to 0.29)
Day 70.14 (-0.11 to 0.39)0.15 (0.01 to 0.28)
Day 140.08 (-0.17 to 0.33)0.18 (0.05 to 0.32)
Day 210.14 (-0.11 to 0.4)0.13 (-0.01 to 0.26)
Day 28-0.01 (-0.26 to 0.25)0.19 (0.05 to 0.32)
SecondaryChange in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
Baseline, Day 14, Day 28
Reported as:
Least squares mean · units on a scale
Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b
units on a scaleGroup 1: VX-661 10 mg qdGroup 2a: VX-661 30 mg qdGroup 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12hGroup 3a: VX-661 100 mg qdGroup 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12hGroup 4: VX-661 100 mg qd/Ivacaftor 150 mg q12hGroup 5a: VX-661 150 mg qdGroup 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12hGroup 1-5b Combined Placebo
PB Through Day 284.02 (-4.38 to 12.43)5.54 (-2.72 to 13.79)3.8 (-1.74 to 9.35)0.61 (-7.64 to 8.86)3.52 (-2.02 to 9.06)5.15 (-0.88 to 11.19)2.58 (-5.21 to 10.37)7.62 (1.78 to 13.45)1.69 (-3.1 to 6.48)
Day 146.67 (-2.9 to 16.25)4.84 (-4.73 to 14.41)4.29 (-2.09 to 10.67)0.27 (-9.3 to 9.83)2.81 (-3.56 to 9.19)4.41 (-2.58 to 11.4)4.13 (-4.9 to 13.16)7.13 (0.37 to 13.89)0.53 (-4.99 to 6.05)
Day 281.38 (-8.7 to 11.45)6.23 (-3.34 to 15.8)3.31 (-3.21 to 9.84)0.95 (-8.61 to 10.52)4.22 (-2.29 to 10.74)5.9 (-1.1 to 12.89)1.03 (-8 to 10.06)8.1 (1.34 to 14.87)2.85 (-2.76 to 8.46)
SecondaryChange in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.

Time frame:
Baseline, Day 14, Day 28
Reported as:
Least squares mean · units on a scale
Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6
units on a scaleGroup 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12hGroup 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12hGroup 4 and 6 Combined: Placebo
Post-Baseline Through Day 280.87 (-4.44 to 6.19)1.91 (-3.5 to 7.33)1.65 (-4.18 to 7.49)
Day 142.02 (-3.97 to 8.02)0.87 (-5.25 to 6.99)2.78 (-3.76 to 9.32)
Day 28-0.27 (-6.27 to 5.72)2.96 (-3.16 to 9.08)0.53 (-6.18 to 7.23)
SecondaryChange in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
Baseline, Day 14, Day 28
Reported as:
Least squares mean · units on a scale
Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7
units on a scaleGroup 7: PlaceboGroup 7: VX-661 100 mg qd
Post-Baseline Through Day 28-3.02 (-13.52 to 7.47)3.79 (-1.78 to 9.36)
Day 141.83 (-10.64 to 14.3)5.24 (-1.56 to 12.04)
Day 28-7.87 (-20.34 to 4.6)2.33 (-4.24 to 8.91)
SecondaryArea Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661 After Administration of VX-661 Monotherapy

Participants who received VX-661 monotherapy (Group 1, 2a, 3a and 5a) were analyzed for this outcome measure. PK analysis (AUC0-24h) was not planned for placebo reporting arms.

Time frame:
Day 28
Reported as:
Mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661 After Administration of VX-661 Monotherapy
nanogram*hour per milliliter (ng*hr/mL)Group 1: VX-661 10 mg qdGroup 2a: VX-661 30 mg qdGroup 3a: VX-661 100 mg qdGroup 5a: VX-661 150 mg qd
Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661 After Administration of VX-661 Monotherapy6260 ± 265023000 ± 655088100 ± 5110098900 ± 20200
SecondaryAUC0-24h of VX-661 and AUC0-12h of Ivacaftor After Administration of VX-661 in Combination With Ivacaftor

Participants who received VX-661 in combination with Ivacaftor (Group 2b, 3b, 4, 5b, 6a, 6d and 7) were analyzed for this outcome measure. PK analysis was not planned for placebo reporting arms.

Time frame:
Day 28
Reported as:
Mean · ng*h/mL
AUC0-24h of VX-661 and AUC0-12h of Ivacaftor After Administration of VX-661 in Combination With Ivacaftor
ng*h/mLGroup 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12hGroup 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12hGroup 4: VX-661 100 mg qd/Ivacaftor 150 mg q12hGroup 5b: VX-661 150 mg qd/ Ivacaftor 150 mg q12hGroup 6a: VX-661 100 mg qd/ Ivacaftor 50 mg q12hGroup 6d: VX-661 50 mg q12h/ Ivacaftor 150 mg q12hGroup 7: VX-661 100 mg qd
AUC0-24h of VX-6618950 ± 237026300 ± 587082700 ± 23300138000 ± 4970077600 ± 1780073300 ± 2290090600 ± 30800
AUC0-12h of Ivacaftor10100 ± 438011700 ± 487010900 ± 389016000 ± 104003690 ± 146011700 ± 545012400 ± 6170

Adverse events

Collected over Start of study drug through the Follow-up Visit (Up to Day 56). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1-6d Combined: Placebo—5/33 (15.2%)30/33 (90.9%)
Group 1: VX-661 10 mg qd—1/8 (12.5%)8/8 (100%)
Group 2a: VX-661 30 mg qd—1/8 (12.5%)7/8 (87.5%)
Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h—1/18 (5.6%)15/18 (83.3%)
Group 3a: VX-661 100 mg qd—0/8 (0%)7/8 (87.5%)
Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h—2/19 (10.5%)18/19 (94.7%)
Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h—2/17 (11.8%)9/17 (52.9%)
Group 5a: VX-661 150 mg qd—0/9 (0%)8/9 (88.9%)
Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h—0/17 (0%)17/17 (100%)
Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h—1/19 (5.3%)16/19 (84.2%)
Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h—2/16 (12.5%)16/16 (100%)
Group 7: Placebo—0/4 (0%)2/4 (50%)
Group 7: VX-661 100 mg qd—1/14 (7.1%)12/14 (85.7%)
Most frequent serious events
Most frequent serious events
EventGroup 1-6d Combined: PlaceboGroup 1: VX-661 10 mg qdGroup 2a: VX-661 30 mg qdGroup 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12hGroup 3a: VX-661 100 mg qdGroup 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12hGroup 4: VX-661 100 mg qd/Ivacaftor 150 mg q12hGroup 5a: VX-661 150 mg qdGroup 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12hGroup 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12hGroup 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12hGroup 7: PlaceboGroup 7: VX-661 100 mg qd
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations5/331/81/81/180/81/192/170/90/171/192/160/40/14
PyrexiaGeneral disorders0/331/80/80/180/80/190/170/90/170/190/160/40/14
DiarrhoeaGastrointestinal disorders0/331/80/80/180/80/190/170/90/170/190/160/40/14
GastroenteritisInfections and infestations0/331/80/80/180/80/190/170/90/170/190/160/40/14
ArthritisMusculoskeletal and connective tissue disorders0/330/80/80/180/80/190/170/90/170/190/160/41/14
HaemoptysisRespiratory, thoracic and mediastinal disorders0/330/80/80/180/81/190/170/90/170/190/160/40/14
Most frequent other events
Showing 10 of 187
Most frequent other events
EventGroup 1-6d Combined: PlaceboGroup 1: VX-661 10 mg qdGroup 2a: VX-661 30 mg qdGroup 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12hGroup 3a: VX-661 100 mg qdGroup 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12hGroup 4: VX-661 100 mg qd/Ivacaftor 150 mg q12hGroup 5a: VX-661 150 mg qdGroup 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12hGroup 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12hGroup 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12hGroup 7: PlaceboGroup 7: VX-661 100 mg qd
FatigueGeneral disorders3/334/81/81/181/83/190/171/92/170/191/160/41/14
NauseaGastrointestinal disorders1/331/82/82/181/82/191/174/90/171/195/160/42/14
CoughRespiratory, thoracic and mediastinal disorders6/333/83/82/182/83/192/172/93/174/193/160/44/14
DizzinessNervous system disorders0/330/83/80/180/80/190/171/90/170/191/160/40/14
PyrexiaGeneral disorders2/332/80/80/180/81/190/171/91/171/190/160/42/14
Sputum increasedRespiratory, thoracic and mediastinal disorders2/332/82/82/181/81/192/172/91/172/193/160/40/14
HaemoptysisRespiratory, thoracic and mediastinal disorders2/332/80/80/182/81/191/170/91/170/191/160/41/14
Nasal congestionRespiratory, thoracic and mediastinal disorders1/332/80/80/181/80/190/171/91/172/191/161/41/14
RalesRespiratory, thoracic and mediastinal disorders0/332/80/82/180/81/192/170/91/170/190/161/41/14
Sinus congestionRespiratory, thoracic and mediastinal disorders1/330/80/80/180/80/191/170/92/171/191/161/40/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1-6d Combined: PlaceboGroup 1: VX-661 10 mg qdGroup 2a: VX-661 30 mg qdGroup 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12hGroup 3a: VX-661 100 mg qdGroup 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12hGroup 4: VX-661 100 mg qd/Ivacaftor 150 mg q12hGroup 5a: VX-661 150 mg qdGroup 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12hGroup 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12hGroup 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12hGroup 7: PlaceboGroup 7: VX-661 100 mg qdTotal
Mean30.7 ± 8.4235.3 ± 8.2630.8 ± 6.6328.3 ± 7.0529.1 ± 7.1229.2 ± 6.3931 ± 9.328.2 ± 8.628.2 ± 6.4627.9 ± 5.5832.8 ± 11.9234.5 ± 7.5926.6 ± 7.0129.8 ± 7.97
Sex: Female, Male
Sex: Female, Male(Participants)Group 1-6d Combined: PlaceboGroup 1: VX-661 10 mg qdGroup 2a: VX-661 30 mg qdGroup 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12hGroup 3a: VX-661 100 mg qdGroup 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12hGroup 4: VX-661 100 mg qd/Ivacaftor 150 mg q12hGroup 5a: VX-661 150 mg qdGroup 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12hGroup 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12hGroup 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12hGroup 7: PlaceboGroup 7: VX-661 100 mg qdTotal
Female134463611310773683
Male20441251366712918107
08

Study locations

36 sites
  • Vertex Investigational Site
    Birmingham, Alabama, United States
  • Vertex Investigational Site
    Oakland, California, United States
  • Vertex Investigational Site
    Boise, Idaho, United States
  • Vertex Investigational Site
    Chicago, Illinois, United States
  • Vertex Investigational Site
    Boston, Massachusetts, United States
  • Vertex Investigational Site
    Grand Rapids, Michigan, United States
  • Vertex Investigational Site
    Kansas City, Missouri, United States
  • Vertex Investigational Site
    Long Branch, New Jersey, United States
  • Vertex Investigational Site
    New Hyde Park, New York, United States
  • Vertex Investigational Site
    Chapel Hill, North Carolina, United States
  • Vertex Investigational Site
    Cincinnati, Ohio, United States
  • Vertex Investigational Site
    Columbus, Ohio, United States
  • Vertex Investigational Site
    Oklahoma City, Oklahoma, United States
  • Vertex Investigational Site
    Hershey, Pennsylvania, United States
  • Vertex Investigational Site
    Pittsburgh, Pennsylvania, United States
  • Vertex Investigational Site
    Charleston, South Carolina, United States
  • Vertex Investigational Site
    Salt Lake City, Utah, United States
  • Vertex Investigational Site
    Burlington, Vermont, United States
  • Vertex Investigational Site
    Seattle, Washington, United States
  • Vertex Investigational Site
    Calgary, Alberta, Canada
  • Vertex Investigational Site
    Vancouver, British Columbia, Canada
  • Vertex Investigational Site
    Halifax, Nova Scotia, Canada
  • Vertex Investigational Site
    Toronto, Ontario, Canada
  • Vertex Investigational Site
    Erlangen, Bayern, Germany
  • Vertex Investigational Site
    Frankfurt, Hessen, Germany
  • Vertex Investigational Site
    Hannover, Niedersachsen, Germany
  • Vertex Investigational Site
    Koeln, Nordrhein Westfalen, Germany
  • Vertex Investigational Site
    Berlin, Germany
  • Vertex Investigational Site
    Bochum, Germany
  • Vertex Investigational Site
    Jena, Germany
  • Vertex Investigational Site
    Munich, Germany
  • Vertex Investigational Site
    Cambridge, Cambridgeshire, United Kingdom
  • Vertex Investigational Site
    London, Greater London, United Kingdom
  • Vertex Investigational Site
    Manchester, Greater Manchester, United Kingdom
  • Vertex Investigational Site
    Southhampton, Hampshire, United Kingdom
  • Vertex Investigational Site
    Cardiff, Vale Of Glamorgen, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 4 years 1 month after primary completion. A results delay was requested in May 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2012
First posted
Feb 13, 2012
Start
Feb 2012
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Results delay requested
May 5, 2015
Results first posted
Apr 13, 2018
Last update
Apr 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01531673
Responsible party
Sponsor
First posted
Feb 13, 2012
Start date
Feb 2012
Primary completion
Mar 2014
Completion
Mar 2014
Results posted
Apr 13, 2018
Last update
Apr 13, 2018

Study contacts

Scott Donaldson, MD
principal investigator · University of North Carolina

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor

Start the discussion